Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents

Carr,Lindsey;

Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents

February 23, 2022

By Lindsey Carr, Editor

Publication

Video

Contemporary OB/GYN JournalVol 67 No 3

Volume 67

Issue 3

Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

If approved, relugolix, estradiol, and norethindrone acetate tablets (Myfembree; Myovant Sciences, Pfizer) could be game-changing for pain management in women with moderate-to-severe endometriosis pain.

Download Issue PDF

Articles in this issue

Delayed diagnosis of a bowel injury at laparoscopy

In this issue: Adnexal torsion, abnormal uterine bleeding, and endometriosis awareness month

Understanding abnormal uterine bleeding in adolescents

Adnexal torsion requires careful diagnosis, management

Bringing awareness to endometriosis

Celebrating Laura E. Riley, MD

Women with pelvic pain turn to social media for condition information, management

Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents

Prenatal genetic data sharing and privacy risks

Patient perspectives on vulvovaginal candidiasis

Provider bias in contraceptive counseling

Are race, ethnicity, and menopausal status associated with GI symptoms?

Related Content

Contemporary OB/GYN week in review: Gepotidacin approval, placebo efficacy, and more

Celeste Krewson, Assistant Editor

March 28th 2025

Article

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents

Lindsey Carr, Editor;Jessica Y. Shim, MD

March 2nd 2022

Podcast

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

Listen

Image Credit: © rocketclips - stock.adobe.com

Revi System demonstrates positive two-year results for treating urgency urinary incontinence

Morgan Ebert, Managing Editor

February 7th 2025

Article

BlueWind Medical’s Revi System shows strong two-year efficacy and safety for UUI, with symptom reduction and high patient satisfaction.

S4E1: New RNA platform can predict pregnancy complications

February 11th 2022

Podcast

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

Listen